

ALLERGIC RHINITIS AND PREGNANCY – A REVIEW OF THE LITERATURE, WITH RECOMMENDATIONS FOR MANAGEMENT

JW Loock, MB ChB, FCS (SA) ORL

Division of Otorhinolaryngology (ENT), Faculty of Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.

ABSTRACT

Key points

- The concurrence of allergic rhinitis and pregnancy is common.
- The diagnosis of allergic rhinitis is easily and reliably made, by eliciting the characteristic symptoms on history.
- This diagnosis is easily confirmed by using the radioallergosorbent test (RAST) or enzyme-linked immunosorbent assay (ELISA) tests.
- Nasal symptoms, particularly obstruction, are often aggravated in pregnancy, through several possible mechanisms.
- Untreated allergic rhinitis and nasal obstruction affect the quality of life and can impact on the lower airways particularly in the presence of asthma, and indeed on the pregnancy itself.
- The effective management of allergic rhinitis in pregnancy is thus important and can be undertaken in complete safety, and the pregnant patient should not be made to suffer the symptoms.
- Management should be tailored to the needs of the patient, and should be the minimum needed to control the condition. It can include: allergen avoidance; simple non-specific measures; local corticosteroid nasal sprays; oral antihistamines and immunotherapy.
- At present there is no intervention in pregnancy that has been shown to reduce the incidence of atopy in offspring.

DEFINITION

Rhinitis may be defined as a condition of diffuse inflammation of the nasal respiratory mucosa characterised by one or more of the following nasal symptoms: congestion, rhinorrhoea, itch or sneezing.¹

Allergic rhinitis occurs when this inflammation is IgE-mediated, following exposure to allergens.

PREVALENCE

While wide variations in reported prevalence exist, allergic rhinitis is acknowledged to be the most common allergic condition, affecting 10-25% of the population,² is a global phenomenon, and appears to be increasing in prevalence.^{3,4}

Given the common nature of the condition of pregnancy, clearly these conditions co-exist frequently!

Correspondence: Prof JW Loock, Dept of Otorhinolaryngology, University of Stellenbosch, PO Box 19063, Tygerberg 7505. E-mail jwl@sun.ac.za

PREGNANCY AND NASAL PROBLEMS

Clearly all nasal diseases can occur with the same frequency in pregnancy as they do in the non-pregnant population.

While allergic rhinitis is a very common condition, the clinician must remember the other nasal conditions which can cause these nasal symptoms. Table I lists the differential diagnosis. Table II lists the predisposing causes of the subgroup of 'non-allergic non-infectious rhinitis'.

Table I. Differential diagnosis of allergic rhinitis

Infectious rhinosinusitis (nonspecific)
Specific rhinosinusitis
– tuberculosis (TB)
– sarcoid
– syphilis
– leprosy, etc.
Non-allergic non-infectious rhinitis (see Table II)
Mechanical nasal obstruction:
– deviated septum
– hypertrophic turbinates
Tumours:
– nose/nasopharynx
– benign (e.g. polyps)/malignant
Cerebrospinal fluid (CSF) rhinorrhoea

Table II. Non-allergic non-infectious inflammation of the nose and sinuses

Occupational
Non-allergic rhinitis with eosinophilia syndrome ('NARES') (like allergic rhinitis, but IgE levels and skin tests are normal)
Hormonal: puberty, pregnancy, menstrual, postmenopausal
Drug-induced: systemic: aspirin, NSAIDs, antihypertensives, etc.
Local: sympathomimetic overuse (rhinitis medicamentosa); cocaine
Irritants: pollution; air-conditioning; cold air
Food intolerance (Note: This is not true IgE-mediated allergy)
Emotional, probably autonomic mediated (stress, sexual ('honeymoon rhinitis'))
Atrophic rhinitis: primary or secondary
Gastro-oesophageal reflux
'Idiopathic rhinitis' or 'vasomotor rhinitis'.
NSAIDs – nonsteroidal anti-inflammatory drugs.

It is however recognised that certain specific associations exist between pregnancy and nasal conditions.

Congestion and inflammation of the nose (and sinuses) are recognised as occurring in pregnancy⁶⁻⁹ as a result of hormonal factors (see Table II). A persistent rhinosinusitis may accompany the last trimester of pregnancy, when the severity increases as the blood oestrogen level increases. Symptoms normally resolve shortly after delivery.

Infectious sinusitis seems to be increased in pregnancy and reportedly complicated as many as 1.5% of pregnancies, a six-fold increase over the frequency that was observed in a non-pregnant population.⁸

A lobular capillary haemangioma ('pyogenic granuloma', 'granuloma gravidarum' or 'pregnancy tumour') is a recognised but uncommon red-brown lesion arising on the nasal septum or inferior turbinate which may produce troublesome bleeding. While it generally resolves post partum, cautery or excision may be indicated.

As regards the relationship between pregnancy and allergic rhinitis, it is variously reported that pre-existing rhinitis may improve, stay unchanged, or worsen in pregnancy. Foxen and colleagues⁹ suggested that nasal allergy can be exacerbated or initiated by pregnancy. Other investigators have refuted this. Schatz¹⁰ has reported both improvement and deterioration of symptoms in women with perennial rhinitis during pregnancy.

PREGNANCY AND ALLERGIC RHINITIS

What, then, should the general practitioner and the specialist in obstetrics and gynaecology know about allergic rhinitis in pregnancy?

Diagnosis

The lay public too often labels all nasal symptomatology indiscriminately as 'sinus' or 'hay fever'. A definite diagnosis should always be made for nasal symptoms.

Fortunately, the diagnosis of allergic rhinitis is extremely easily and reliably made. The basis of diagnosing allergic rhinitis is the history, and the symptoms are remarkably accurate (Table III).

Table III. Symptoms specific to allergic rhinitis

Itch: nasal/conjunctival/palatal
Sneezing many times in a row
Watery discharge; rhinorrhoea/lacrimation
Reaction to specific allergens/situations: house dust; making beds; pollen; cats; dogs; feathers
Seasonal nature (although perennial nature does not exclude diagnosis)
Asthma/eczema
Family history of hay fever/asthma/eczema.

Examination is far less reliable, and identification of the classic 'pale blue' swollen, wet, inferior turbinates requires good lighting, a degree of experience and arguably a nasal speculum to achieve – and even then it is far less reliable than the history.

Specialty consultation with otorhinolaryngologists or allergologists may assist if the diagnosis is uncertain.

Confirmation of the diagnosis is done by either blood (radioallergosorbent test (RAST) or enzyme-linked immunosorbent assay (ELISA)) tests or the far cheaper and equally reliable skin-prick tests; both options are probably safe in pregnancy, but because of the small risk of hypersensitivity reaction, blood tests are advised in the pregnant state.

Computed tomography (CT) scanning of the nose and sinuses is almost never necessary for allergic rhinitis. It is useful in excluding other nasal problems, particularly sinusitis. However, while the dose of radiation from current spiral CT scans is far less than it used to be, and the fetus can theoretically be shielded, radiologists are extremely reluctant to undertake CT scanning in

pregnancy unless absolutely necessary, because of the issue of radiation scatter.

Management

The management of allergic rhinitis rests upon five limbs: allergen avoidance; the use of corticosteroids (intramuscular, oral or local nasal sprays); the administration of antihistamines (oral or eye drops); hypo- or desensitisation (intradermal injection or sublingual); and occasionally surgery (cautery, injection or reduction of hypertrophied turbinates). The use of mast-cell stabilisers, e.g. sodium cromoglycate or leukotriene antagonists, has been found by most clinicians to be disappointing.

Allergen identification and avoidance

The identification of allergens and instigation of allergen avoidance makes complete sense, and clearly puts the fetus at no risk. Symptoms of allergic rhinitis can be significantly mitigated by avoiding the allergen when this is possible. Local allergy societies often put out useful and convenient leaflets for doctors and patients.

No treatment and simple non-specific measures

There are times when, despite the diagnosis of allergic rhinitis, the symptoms are mild and no treatment is required. Nonspecific treatment measures may include the use of external nasal dilators, avoidance of irritants, and humidification. Nasal saline drops or sprays are a useful and safe option to help clear the nose, particularly before eating or sleeping.¹¹

Pharmacological intervention

Clearly it is a concern in pregnancy that the administration of systemic and even local pharmacotherapy might have a deleterious effect on the fetus. Caution is always advised when administering a drug to a pregnant woman, as most medications cross the placenta. The risk of fetal malformation represents a major fear and is highest during the first trimester, the time of most organogenesis.

Fear of the possible teratogenicity of medication used for allergic rhinitis is largely based upon animal experiments and isolated associations in case reports. However medication is often avoided in pregnancy even when necessary, because of alarming information on drug labels or encountered in patient education.

These cautions should be balanced against the fact that upper airway disease, if uncontrolled, has a significant, negative effect on quality of life, and several studies have shown that it can exacerbate coexisting asthma, which might in turn adversely affect the outcome of a pregnancy.¹² Furthermore, nasal obstruction may affect the pregnant mother's eating, sleeping and emotional well-being, which indirectly could adversely affect pregnancy.¹³ For example, rhinitis during pregnancy may cause significant upper airway obstruction during sleep, which has been associated with pregnancy-induced hypertension and intrauterine growth retardation.¹⁴

Medication is therefore indicated based on an exact clinical diagnosis, when the benefit of the drug outweighs risk, and when the drugs are carefully chosen and appropriately administered. Under these circumstances, risk should be negligible.

In 1979 the US Food and Drug Administration (FDA) published a drug classification system¹⁵ to assist in understanding the risk of any specific drug. It has five pregnancy precaution categories: A, B, C, D and X (Table IV).

Table IV. Food and Drug Administration format for labelling human prescription drugs

Category	Description of risk
A	Well-controlled human studies have failed to demonstrate risk to the fetus.
B	Either animal studies show no fetal risk and no human data are available, or animal studies show a risk but human studies do not show fetal risk.
C	Either animal studies indicate a fetal risk and there are no controlled studies in humans, or there are no available studies in humans or animals.
D	Studies show fetal risk in humans, but potential benefits may outweigh the potential risk in certain situations.
X	Studies in animals or humans, or based on human experience show definite fetal risk.

Glucocorticosteroids

Systemic glucocorticosteroids are teratogenic in animals. The principal malformations are cleft lip and palate, and cardiovascular malformation.¹⁶ Systemic steroids are generally used by otorhinolaryngologists as short courses to unblock the nose quickly at the start of treatment or as somewhat more prolonged courses for very severe symptoms during the hay fever season. The hormonal side-effects of prolonged administration even in the nonpregnant patient are widely accepted as precluding such use. Prolonged systemic corticosteroids in pregnant women have been implicated in growth retardation¹⁷ and pre-eclampsia.¹⁰ Although the evidence for their teratogenic effects in pregnancy in humans is poor, concerns exist about possible increased risk of cleft lip or palate in the first trimester.¹⁸

It would seem sensible to avoid even these short courses of systemic corticosteroids in pregnancy, whenever possible – certainly in the first trimester.

The small concentrations of corticosteroids passed by the lactating mother to the infant present no substantial threat.

Inhaled glucocorticosteroids, by contrast, have been extensively used by pregnant women who have asthma, and have not been incriminated in teratogenicity in humans.¹⁹ Various studies have shown that high drug concentrations can be achieved at receptor sites in the nasal mucosa, with minimal risk of systemic adverse effects as the amount of systemic absorption of nasal steroid sprays is negligible.²⁰ Inhaled corticosteroids are extremely effective particularly for nasal obstruction in allergic rhinitis.²¹ Large retrospective studies have suggested that topical corticosteroids may play a role in reducing the risk of asthma exacerbation.^{22,23} A review of the use of budesonide in pregnancy showed no risk to the fetus in 6 600 pregnancies.²⁴ In a randomised, double-blind, placebo-controlled study that looked at the efficacy of fluticasone propionate nasal spray in pregnancy, no effects on the outcomes of the pregnancies were found.²⁵

Based on their efficacy, their limited systemic absorption, and the existing studies, nasal steroid sprays would seem to be a useful, effective and safe first-line option for use in pregnancy, particularly for nasal obstruction, and particularly after the first trimester. The FDA has assigned intranasal budesonide to category B; all other inhaled and intranasal corticosteroids are rated category C, although they are probably as safe.

It is important for the clinician to emphasise and demonstrate the correct use of nasal steroid sprays, both consistent and compliant use, and administration by the correct technique, to ensure optimal benefit (Table V and Figs 1-4 which demonstrate incorrect (Figs 1 & 2) and correct (Figs 3 & 4) technique).

Table V. Instructions to patients for correct administration of nasal sprays

1. Hold your head in the normal upright position.
2. Place the tip of the nozzle in one nostril.
3. Hold the bottle at 45° to the horizontal.
4. Aim slightly away from the midline of the nose, i.e. towards the outer wall of your nasal passage.
5. Give a spray into the nostril, breathing in slightly through the nose. DO NOT SNIFF DEEPLY.
6. Give a second spray as in 5.
7. Now repeat steps 2-6 for the other nostril.
8. DO NOT BLOW YOUR NOSE FOR 15 MINUTES.

NOTE: Step 4 can be achieved by either of the following instructions:

- * 'With the nozzle in your nostril aim for the outer corner of the eye'
- OR
- * 'Use your right hand for the left nostril, and your left hand for the right nostril'.



Fig. 1. Incorrect angle towards nasal septum.



Fig. 2. Incorrect direction – held too vertically.



Fig. 3. Correct angle to lateral wall of nose.



Fig. 4. Correct 45° angle.

Antihistamines

Antihistamines are effective for the irritating symptoms of watery rhinorrhoea, itch and sneezing, but have until recently been considered to have little or no effect on nasal congestion.²⁶ The latest agents claim to be more effective for congestion.²⁷ Antihistamines for nasal symptoms need to be taken systemically, so clearly, safety of the fetus must be considered. While some first-generation antihistamines were shown to be teratogenic in animals,²⁸⁻³⁰ a large meta-analysis of 200 000 first-trimester exposures to first-generation antihistamines³¹ failed to show increased teratogenic risk in humans, and they are rated FDA category B. The newer second-generation antihistamines which have less central sedation than their predecessors have been less well studied. Isolated reports of teratogenicity in animal models and the possibility of hypospadias in human offspring raised concerns,³² but follow-up studies³³ dispelled these concerns and a cohort of 2 147 women exposed to loratidine did not show risk of major congenital malformations.³⁴ Data from the Swedish Medical Birth Registry showed no increased incidence of congenital malformations in 917 exposures to cetirizine in pregnancy.³²

Decongestants

Sympathomimetic vasoconstrictor agents are not specific for allergic rhinitis, but at times are used in nasal congestion for short-term relief. Their prolonged use, particularly topically, may lead to tachyphylaxis, rebound congestion and 'rhinitis medicamentosa'.

Oral decongestants are sometimes used alone, and at times in combination with antihistamines. Most oral decongestants are teratogenic in animals. Pseudoephedrine use in the first trimester has been implicated in an increased incidence of gastroschisis.³⁵ It carries an FDA category C rating. It can be considered after the first trimester when the danger of gastroschisis has passed.

There are no specific data available concerning the use of decongestants during lactation. Pseudoephedrine does pass into the breast milk. It is recommended that only short-acting forms (e.g. phenylephrine) be used, and taken just after breastfeeding to minimise the concentration in breast milk.

Topical nasal decongestants (nasal or ophthalmic). While it would seem logical that these are safer than oral agents, there are no adequate studies on the safety of administration. These drugs therefore carry an FDA category C rating. The limited data available suggest that their use should be limited to severe nasal congestion interfering with sleep, only when really required, preferably after the first trimester and not during labour.

Leukotriene modifiers

The use of leukotriene modifiers, e.g. zileuton, montelukast and zafirlukast, cannot be supported because of lack of evidence on their safety and the existence of more effective agents with more data on human gestational safety.

Mast-cell stabilisers

Mast-cell stabilisers, e.g. sodium cromoglycate, are virtually not absorbed by mucosal surfaces, and considered entirely safe, but, as stated previously, are far less effective than nasal steroids. No teratogenic effect has been found in animals and no adverse effect shown in humans.³⁶ They carry an FDA category B rating.

Anticholinergic agents

Intranasal ipratropium bromide is poorly absorbed by the nasal mucosa, has no record of teratogenicity in animal studies, and appears safe. However, while it is effective in controlling watery nasal discharge, it does not affect nasal obstruction or other symptoms, which limits its usefulness; and adequate studies in humans are lacking.

Allergen-specific immunotherapy

Allergen-specific immunotherapy ('SIT', 'hyposensitisation' or 'desensitisation') is based upon the repeated exposure of the allergic individual to an extract of the allergen in order to induce a state of immunological tolerance. It is generally used in patients who fail to respond adequately to avoidance, nasal steroids and antihistamines. It is less effective in patients with a wide spectrum of allergens, which is a common situation, and this limits its usefulness. It may be administered by intradermal or sublingual routes ('SLIT'). Systemic reactions may occur in up to 10% of patients, although these are usually mild.³⁷ There have been a number of case reports of women who have used immunotherapy during pregnancy for the treatment of allergic rhinitis and asthma without any adverse outcomes reported.³⁴ Metzger *et al.*³⁸ showed the safety of SIT in a study of 115 pregnant women with allergic rhinitis. It would seem unwise to initiate immunotherapy in a pregnant patient, but pregnancy is not considered to be a contraindication to the continuation of immunotherapy.^{39,40}

FACTORS IN PREGNANCY INFLUENCING THE INCIDENCE OF ALLERGIC RHINITIS IN OFFSPRING

There are several publications in the literature examining the possibility that fetal exposure *in utero* might translate into subsequent atopy. Possible influencing factors studied include: previous use of oral contraceptives;⁴¹ maternal occupation;⁴² maternal respiratory infection;⁴³ smoking exposure;⁴⁴ caesarean section delivery;⁴⁵ dietary supplementation;⁴⁶ and maternal dietary antigen avoidance during pregnancy and/or lactation.

Most of these articles represent low levels of evidence (level 3 and poorer). However a Cochrane review of the effect of maternal dietary antigen avoidance during pregnancy and lactation concluded that this is unlikely to reduce the child's risk of atopic diseases and that such a diet may adversely affect fetal and/or maternal nutrition.⁴⁷

CONCLUSION

This article attempts to review the current evidence-based literature on allergic rhinitis and pregnancy, in the hope of assisting clinicians in treating patients who require treatment in confidence and safety. The reference list includes other worthwhile reviews, which have been marked thus †.^{34, 39, 48}

Declaration of conflict of interest

The author declares no conflict of interest.

REFERENCES

1. International Rhinitis Management Working Group. International Consensus Report on the diagnosis and management of rhinitis. *Allergy* 1994; **49** (Suppl. 19): 1-34.
2. Bousquet J, van Cauwenberge P, Khaltaev N, et al. *World Health Organization Initiative on Allergic Rhinitis and its Impact on Asthma*. Geneva: WHO, 2000: 1-214.
3. Aberg N, Hesselmar B, Aberg B, Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. *Clin Exp Allergy* 1995; **25**: 815-819.
4. Leynaert B, Neukrich F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and allergic rhinitis co-morbidity. *J Allergy Clin Immunol* 2000; **106**: S201-205.
5. Jacobs RL. Non-allergic chronic rhinitis syndromes. *Immunol Allergy Clin North Am* 1987; **7**: 93.
6. Mabry RL. Rhinitis of pregnancy. *South Med J* 1986; **79**: 965-971.
7. Ellegard A, Karlsson G. Nasal congestion during pregnancy. *Clin Otolaryngol* 1999; **24**: 307-311.
8. Sorri M, Bortikanen-Sorri AL, Karja J. Rhinitis during pregnancy. *Rhinology* 1980; **18**: 83-86.
9. Foxen EH, Preston TD, Lack JA. The assessment of nasal airflow: a review of past and present methods. *J Laryngol Otol* 1971; **85**: 811-825.
10. Schatz M. Special considerations for the pregnant woman and senior citizens with airway disease. *J Allergy Clin Immunol* 1998; **101**: 5373-5378.
11. Nuutinen J, Holopainen E, Haahtela T, Ruoppi P, Silvasti M. Balanced physiological saline in the treatment of chronic rhinitis. *Rhinology* 1986; **24**: 265-269.
12. Guerra S, Sherril DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. *J Allergy Clin Immunol* 2002; **109**: 419-425.
13. Schatz M, Zeiger RS. Asthma and allergy in pregnancy. *Clin Perinatol* 1997; **24**: 407-432.
14. Franklin KA, Holmgren PA, Jonsson F, Poromaa N, Stenlund H, Svanborg E. Snoring, pregnancy-induced hypertension, and growth retardation of the fetus. *Chest* 2000; **117**: 137-141.
15. Food and Drug Administration. Labeling and prescription drug advertising: content and format for labeling for human prescription drugs (final rule). *Fed Regist* 1979; **44**(124): 37434-37467.
16. Kusanagi T. Occurrence of cleft palate, palatal slit, and fetal death in mice treated with a glucocorticoid: an embryo transfer experiment. *Teratology* 1983; **27**: 395-400.
17. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. *Science* 1978; **202**: 436-438.
18. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. *Teratology* 2000; **62**: 385-392.
19. Briggs GC, Freeman RK, Yaffe SJ. *Drugs in Pregnancy and Lactation – a Reference Guide to Fetal and Neonatal Risk*, 8th ed. Baltimore: Lippincott Williams & Wilkins; 1998.
20. Scadding GK. Safety of intranasal steroids. *Current Opinion in Otolaryngology and Head and Neck Surgery*. London: RSM Publications, 2002.
21. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. *BMJ* 1998; **317**: 1624-1629.
22. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. *J Allergy Clin Immunol* 2002; **109**: 636-642.
23. Crystal-Peters J, Nelusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with co-morbid asthma: the risk of asthma-related emergency department visits. *J Allergy Clin Immunol* 2002; **109**: 57-62.
24. Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. *Curr Med Res Opin* 2005; **21**: 1075-1084.
25. Ellegard EK, Helligren M, Karlsson NG. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. *Clin Otolaryngol* 2001; **26**: 394-400.
26. Bousquet J, Campbell A, Michel F. Antiallergic activities of antihistamines. In: Church M, Rihoux J, eds. *Therapeutic Index of Antihistamines*. Lewiston, NY: Hogrefe & Huber, 1992: 57-95.
27. Horak F, Stubner UP, Ziegelmayr R, Ing D, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in patients with grass pollen-induced allergic rhinitis in an allergen-exposure unit. *J Allergy Clin Immunol* 2002; **109**: 956-961.
28. Walker BE, Patterson A. Induction of cleft palate in mice by tranquilizers and barbiturates. *Teratology* 1974; **10**: 159-163.
29. King CT, Howell J. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. *Am J Obstet Gynecol* 1966; **95**: 109-111.
30. Saxen I. Cleft palate and maternal diphenhydramine intake. *Lancet* 1974; **i**: 407-408.
31. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. *Am J Perinatol* 1997; **14**: 119-124.
32. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. *J Matern Fetal Neonatal Med* 2002; **11**: 146-152.
33. Kallen B, Olausson PO. No increased risk of infant hypospadias after maternal use of loratidine in early pregnancy. *Int J Med Sci* 2006; **3**: 106-107.
- 34.† Gilbert C, Mazzotta P, Loebstein R, Koren G. Fetal safety of drugs used in the treatment of allergic rhinitis. *Drug Saf* 2005; **28**: 707-719.
35. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. *Teratology* 1992; **45**: 361-367.
36. Wilson J. Use of sodium cromoglycate during pregnancy. *Acta Theriol (Warsz)* 1982; **8**: S45-51.
37. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy Asthma Immunology. *Ann Allergy Asthma Immunol* 1998; **81** (5 pt 1): 401-405.
38. Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. *J Allergy Clin Immunol* 1978; **61**: 268-272.
- 39.† Piette V, Daures JP, Demoly P. Treating allergic rhinitis in pregnancy. *Curr Allergy Asthma Rep* 2006; **6**: 232-238.
40. Shaikh WA. A retrospective study on the safety of immunotherapy in pregnancy. *Clin Exp Allergy* 1993; **23**: 857-860.
41. Keski-Nisula L, Pekkanen J, Xu B, Putus T, Koskela P. Does the pill make a difference? Previous maternal use of contraceptive pills and allergic diseases among offspring. *Allergy* 2006; **61**: 1467-1472.
42. Magnusson LL, Wennborg H, Bonde JP, Olsen J. Wheezing, asthma, hay fever, and atopic eczema in relation to maternal occupations in pregnancy. *Occup Environ Med* 2006; **63**: 640-646. Epub 2006 June 6.
43. Zutavern A, von Klot S, Gehring U, Krauss-Etschmann S, Heinrich J. Pre-natal and post-natal exposure to respiratory infection and atopic diseases development: a historical cohort study. *Respir Res* 2006; **7**: 81.

44. Magnusson LL, Olesen AB, Wennborg H, Olsen J. Wheezing, asthma, hay fever, and atopic eczema in childhood following exposure to tobacco smoke in fetal life. *Clin Exp Allergy* 2005; **35**: 1550-1556.
45. Renz-Polster H, David MR, Buist AS, *et al.* Caesarean section delivery and the risk of allergic disorders in childhood. *Clin Exp Allergy* 2005; **35**: 1466-1472.
46. Miyake Y, Sasaki S, Ohya Y, *et al.* The Osaka Maternal and Child Health Study Group. Dietary intake of seaweed and minerals and prevalence of allergic rhinitis in Japanese pregnant females: baseline data from the Osaka Maternal and Child Health Study. *Ann Epidemiol* 2006; **16**: 614-621. Epub 2006 Jan 10.
47. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. *Cochrane Database Syst Rev* 2006; **3**: CD000133.
48. [†]Incaudo GA, Takach P. The diagnosis and treatment of allergic rhinitis during pregnancy and lactation. *Immunol Allergy Clin North Am* 2006; **26**: 137-154.

*** Note: the most important reviews are marked [†].**

Search strategy: A Pubmed search for the words 'allergic rhinitis' and 'pregnancy' delivered 71 articles; from these the 20 most relevant were selected. Further references were sourced from their reference lists.

PATIENT INFORMATION SHEETS – ANOTHER ALLSA MEMBERSHIP BENEFIT

Did you know that membership of ALLSA entitles you to receive copies of our Patient Information Sheets which provide information on various aspects of allergy in an easy-to-understand format for your patients?

Topics covered include:

Allergen Immunotherapy
 Allergic Reactions to Honey Bee and Wasp Stings
 Allergic Rhinitis
 Bedding Protectors and Allergy Control
 Cockroach Allergy
 Coeliac Disease
 Contact Dermatitis
 Drug Allergy
 Egg Allergy
 Fish Allergy
 Food Additives and Preservatives
 Food Allergy
 House-Dust Mite Allergy
 Latex Allergy
 Milk Allergy/Intolerance
 Mould Allergy
 Peanut Allergy
 Pet Allergy
 Seafood Allergy
 Soya Allergy
 Treatment of Allergic Eczema
 Urticaria and Angioedema
 Vacuuming and Allergy Control
 Wheat Allergy

Patient information sheets can be ordered in batches of 50 from the ALLSA office, tel 021-447-9019, email mail@allergysa.org

There is no charge for the leaflets, but we do charge for postage.